IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award

Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry.

Frost & Sullivan’s annual Customer Value Leadership Award recognizes the company that offers products or services that customers find superior in overall price, performance and quality. IQVIA was awarded this recognition for its Enterprise Quality Management System (eQMS), SmartSolve®, which serves as a single source of truth ecosystem that simplifies the complexity of quality and regulatory compliance.

SmartSolve is an intelligence-driven platform that enables quality assurance and regulatory affairs professionals to improve patient safety, enhance product quality, drive commercial efficiency, process effectiveness and maintain compliance. Similar to all IQVIA AI-powered solutions, IQVIA’s SmartSolve’s eQMS platform is grounded in IQVIA Healthcare-grade AI™, AI engineered to meet the level of precision, speed and trust required for life sciences and healthcare.

“It is an honor to be recognized for our transformative artificial intelligence efforts in the quality and regulatory space,” said Susan Hill, vice president of Global Product Management, Digital Products & Solutions, at IQVIA. “IQVIA empowers industry professionals with a leading Enterprise Quality Management solution that accelerates the provision of safe and effective care globally. This award is a testament to our focus on driving innovation and simplifying complex processes for our customers.”

“IQVIA’s differentiated strategy combines intelligence-driven simplification, integration and automation to transform quality operations and drive efficiency for QA/RA professionals,” said Sankara Narayanan, industry director at Frost & Sullivan. “With tailored, customer-centric solutions that leverage AI to streamline workflows, provide insights into individual activities and drive operational improvements, IQVIA prioritizes patient safety and enhances commercial performance.”

Discover how SmartSolve can enhance your quality management processes by visiting our website. Read Frost & Sullivan’s full report here to learn more about IQVIA’s recognition and the benefits of the SmartSolve platform.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240919580830/en/

Kerri Joseph, IQVIA Investor Relations ([e-mail]) +1.973.541.3558

Trent Brown, IQVIA Media Relations ([e-mail]) +1.919.780.3221